Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 390

1.

Posterior fossa recurrence of WHO grade II and III supratentorial gliomas.

Terziev R, Petrirena G, Marie Y, Mueller WC, Bielle F, Delattre JY.

Rev Neurol (Paris). 2018 Oct 9. pii: S0035-3787(17)30583-0. doi: 10.1016/j.neurol.2017.10.018. [Epub ahead of print]

PMID:
30314742
2.

Cognitive impairment and morphological changes after radiation therapy in brain tumors: A review.

Jacob J, Durand T, Feuvret L, Mazeron JJ, Delattre JY, Hoang-Xuan K, Psimaras D, Douzane H, Ribeiro M, Capelle L, Carpentier A, Ricard D, Maingon P.

Radiother Oncol. 2018 Aug;128(2):221-228. doi: 10.1016/j.radonc.2018.05.027. Epub 2018 Jul 2. Review.

PMID:
30041961
3.

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Jul 17. pii: theoncologist.2017-0495. doi: 10.1634/theoncologist.2017-0495. [Epub ahead of print]

PMID:
30018130
4.

Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.

Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Desestret V, Honnorat J.

J Neurol. 2018 Jul 12. doi: 10.1007/s00415-018-8970-0. [Epub ahead of print]

PMID:
30003358
5.

New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study.

Bompaire F, Lahutte M, Buffat S, Soussain C, Ardisson AE, Terziev R, Sallansonnet-Froment M, De Greslan T, Edmond S, Saad M, Nioche C, Durand T, Alamowitch S, Xuan KH, Delattre JY, Renard JL, Taillia H, Chargari C, Psimaras D, Ricard D.

Support Care Cancer. 2018 Dec;26(12):4217-4226. doi: 10.1007/s00520-018-4296-9. Epub 2018 Jul 7.

PMID:
29982900
6.

Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.

Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, Sanson M, Delattre JY, Honnorat J, Desestret V, Alentorn A.

Br J Cancer. 2018 Jul;119(1):105-113. doi: 10.1038/s41416-018-0125-7. Epub 2018 Jun 14.

PMID:
29899393
7.

FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.

PMID:
29728520
8.

Foreword.

Delattre JY.

Rev Neurol (Paris). 2018 Apr;174(4):181. doi: 10.1016/j.neurol.2018.04.001. No abstract available.

PMID:
29678271
9.

Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.

PMID:
29549621
10.

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.

PMID:
29520610
11.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.

12.

Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.

Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19.

13.

Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma.

Le Fèvre R, Durand-Dubief M, Chebbi I, Mandawala C, Lagroix F, Valet JP, Idbaih A, Adam C, Delattre JY, Schmitt C, Maake C, Guyot F, Alphandéry E.

Theranostics. 2017 Oct 13;7(18):4618-4631. doi: 10.7150/thno.18927. eCollection 2017.

14.

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.

PMID:
29143276
15.

Brain volumetric analysis and cortical thickness in adults with saccadic intrusions (ocular flutter or opsoclonus-myoclonus syndrome).

Ibáñez-Juliá MJ, Pappa E, Gaymard B, Leclercq D, Hautefort C, Tilikete C, Delattre JY, Hoang-Xuan K, Psimaras D, Alentorn A.

Clin Neurol Neurosurg. 2017 Dec;163:167-172. doi: 10.1016/j.clineuro.2017.10.028. Epub 2017 Oct 31.

PMID:
29121544
16.

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.

17.

Improving diagnosis and management of primary brain tumors.

Delattre JY.

Curr Opin Neurol. 2017 Dec;30(6):639-642. doi: 10.1097/WCO.0000000000000500. No abstract available.

PMID:
28906269
18.

Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

J Control Release. 2017 Sep 28;262:259-272. doi: 10.1016/j.jconrel.2017.07.020. Epub 2017 Jul 13.

PMID:
28713041
19.

Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

Biomaterials. 2017 Oct;141:210-222. doi: 10.1016/j.biomaterials.2017.06.026. Epub 2017 Jun 21.

PMID:
28689117
20.

Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing.

Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau M, Schmitt C, Masliah-Planchon J, Bourdeaut F, Dehais C, Marie Y, Delattre JY, Idbaih A.

Acta Neuropathol. 2017 Nov;134(5):691-703. doi: 10.1007/s00401-017-1743-5. Epub 2017 Jun 21.

Supplemental Content

Loading ...
Support Center